NCT05732285

Brief Summary

The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions. The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 17, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

October 20, 2025

Status Verified

October 1, 2025

Enrollment Period

2 years

First QC Date

February 7, 2023

Last Update Submit

October 15, 2025

Conditions

Keywords

Affective DysfunctionCognitive Behavioral TherapyModifiable lifestyle factorsCognitive Rehabilitation TherapyLong COVID (coronavirus disease)

Outcome Measures

Primary Outcomes (3)

  • Number of patients that complete the study

    week 8 (end of treatment)

  • Average number of sessions completed

    week 8 (end of treatment)

  • Overall experience based qualitative semi-structured interview

    This interview will be conducted at the end of the study and in the order of exit of participants to gather feedback about their satisfaction with the study. This brief interview consists of 3 questions that ask the participants to describe the aspects of the intervention participants found beneficial, willingness to participate again, and whether it was appropriate for participants needs. In addition, a brief quantitative satisfaction survey to rate overall satisfaction, how likely it would be recommend to others, and how satisfied participants are with telemedicine as a mode of delivery.

    Week 9 (after treatment ended)

Secondary Outcomes (7)

  • The Community Integration Questionnaire (CIQ) Score

    Week 9 (after treatment ended)

  • The Short Form Health Survey (SF-36)

    Week 9 (after treatment ended)

  • Montreal Cognitive Assessment (MoCA)

    Week 9 (after treatment ended)

  • The Symbol Digit Modalities Test Score (SDMT-5 minutes)

    Week 9 (after treatment ended)

  • Brief Visuospatial Memory test (BVMT-R-25 minutes)

    Week 9 (after treatment ended)

  • +2 more secondary outcomes

Study Arms (2)

CRT plus CBT and Lifestyle modifications

EXPERIMENTAL
Behavioral: CRTBehavioral: CBTBehavioral: Modifiable lifestyle factors

Usual care

ACTIVE COMPARATOR
Behavioral: Usual care Psychoeducation

Interventions

CRTBEHAVIORAL

Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy. Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks. All research-related sessions will be web-based (on Zoom) and recorded (with approval).

CRT plus CBT and Lifestyle modifications
CBTBEHAVIORAL

Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy. Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks. All research-related sessions will be web-based (on Zoom) and recorded (with approval).

CRT plus CBT and Lifestyle modifications

The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.

CRT plus CBT and Lifestyle modifications

Participants will receive 15 minute psychoeducation session twice per week for 8 weeks. All research-related sessions will be web-based (on Zoom) and recorded (with approval).

Usual care

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with one of the following: Mild Trauma Brain injury (TBI), Multiple Sclerosis (MS), Long COVID, or Mild Cognitive Impairment (MCI)
  • MCI patients age older than 50 years old, all other diagnosis 21-65 years old and are receiving care through the Michigan medicine network
  • Participants that can provide consent or legally authorized representative who can provide consent on their behalf
  • Cognitive impairment ≥ 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory)

You may not qualify if:

  • TBI participants symptomatic at rest (headache, dizziness, nausea, or vertigo) will be referred to primary care physician (PCP)
  • History of TBI (except for participants with TBI)
  • MS participants with recent relapse (1 month prior to enrollment) or on Intravenous or oral steroids
  • MCI participants with disease duration greater than 1 year
  • Patients with other neurosensory or neurodegenerative diseases
  • Diagnosed with COVID-19 (except for Long COVID group)
  • Psychiatric disorders other than mild to moderate anxiety and depression
  • Patients with severe depression or suicidal (ideation or plan) will be instructed to seek mental health, provided with resources and referred to patient's primary care provider
  • Diagnosed sleep disorders
  • Visual or auditory impairment,
  • Current or history of alcohol or substance abuse/dependence
  • Cognitive impairment less than 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory)
  • Cognitive impairment greater or equal to 1.0 standard deviation below the test score normed for age and education in 1 cognitive domain (verbal learning and memory, processing speed, or visuospatial memory)
  • Currently receiving CRT, CBT or Occupational therapy (OT) or another type of psychological therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Neurocognitive DisordersCognitive DysfunctionBrain Injuries, TraumaticMultiple SclerosisPost-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

Mental DisordersCognition DisordersBrain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesCOVID-19Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Hala Darwish, PhD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Masking Details
Only the data collectors in this study will be blind to the patient's group allocation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: CRT plus CBT plus lifestyle modification or usual care
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Nursing

Study Record Dates

First Submitted

February 7, 2023

First Posted

February 17, 2023

Study Start

September 1, 2023

Primary Completion

September 1, 2025

Study Completion

October 1, 2025

Last Updated

October 20, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations